REC-4881

DRUG3 trials

Sponsors

Recursion Pharmaceuticals Inc.

Conditions

APC Gene MutationAXIN1 Gene MutationFamilial Adenomatous PolyposisSolid Tumor

Phase 1

Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

RecruitingNCT05552755

Recursion Pharmaceuticals Inc.Familial Adenomatous Polyposis

Start: 2023-07-10End: 2027-09-01Target: 67Updated: 2026-06-05

Phase 2

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

TerminatedNCT06005974

Recursion Pharmaceuticals Inc.APC Gene Mutation, AXIN1 Gene Mutation, Solid Tumor

Start: 2024-01-15End: 2025-02-24Updated: 2026-02-23

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Not yet recruitingCTIS2026-525282-50-00

Recursion Pharmaceuticals Inc.Familial Adenomatous Polyposis

Target: 15Updated: 2026-07-13